Search results
Merck to buy EyeBio in a deal that could valued at up to $3 billion
Morningstar· 5 days agoMerck & Co. Inc. (MRK) announced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused biotechnology company, in a deal ...
TILT Biotherapeutics reports data from Phase I trial of ovarian cancer treatment
Clinical Trials Arena via Yahoo Finance· 6 days agoFinnish biotechnology company TILT Biotherapeutics has announced results from a Phase I clinical...
US Duo Takes On Merck's $3B Acquisition Of EyeBio | Law.com International
Law.com· 4 days agoSkadden Arps Slate Meagher & Flom and Gibson Dunn & Crutcher have taken on lead roles in New...
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)
Benzinga· 6 days agoEditor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead...
Summit Therapeutics sees stock soar 272% after lung cancer clinical trial - Silicon Valley Business...
The Business Journals· 4 days ago(Nasdaq: SMMT) — led by the team that scored success with blood cancer drug developer Pharmacyclics...
Merck to Acquire EyeBio
Morningstar· 5 days agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the ...
Summit Shares Soar After Lung Cancer Drug Tops Keytruda in Study
Bloomberg· 4 days agoSummit Therapeutics Inc. shares jumped after the biotech company said a late-stage trial met its...
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
Benzinga· 6 days agoHELSINKI, Finland, May 28, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American
Merck To Pay as Much as $3 Billion for Eye Treatment Startup
Bloomberg· 5 days agoHave a confidential tip for our reporters? Merck & Co. restocked its cabinet of eye treatments with...
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports By Reuters
Investing.com· 6 days agoMerck did not immediately respond to Reuters' request for a comment, while Eyebiotech declined to...